Cargando…
The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer
The L10P single nucleotide polymorphism (SNP) is located in the signal sequence of the transforming growth factor β1 (TGFβ1) gene. The proline-encoding (Pro-) allele of this SNP has been associated with an increased breast cancer risk, which has been attributed to the elevated secretion of this TGFβ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759865/ https://www.ncbi.nlm.nih.gov/pubmed/23887657 http://dx.doi.org/10.3390/ijms140815376 |
_version_ | 1782282697846030336 |
---|---|
author | Taubenschuß, Eva Marton, Erika Mogg, Maurice Frech, Barbara Ehart, Lisa Muin, Dana Schreiber, Martin |
author_facet | Taubenschuß, Eva Marton, Erika Mogg, Maurice Frech, Barbara Ehart, Lisa Muin, Dana Schreiber, Martin |
author_sort | Taubenschuß, Eva |
collection | PubMed |
description | The L10P single nucleotide polymorphism (SNP) is located in the signal sequence of the transforming growth factor β1 (TGFβ1) gene. The proline-encoding (Pro-) allele of this SNP has been associated with an increased breast cancer risk, which has been attributed to the elevated secretion of this TGFβ1 variant observed in vitro and in male subjects. Here we investigated the association of the L10P SNP with serum levels of TGFβ1 in female breast cancer patients and controls. We genotyped the L10P SNP in 276 breast cancer patients and 255 controls. Serum TGFβ1 concentrations were measured by enzyme-linked immunosorbent assay (ELISA) in a subset of the study population (n = 211). We found no evidence for an association of the L10P SNP with breast cancer risk (per-allele odds ratio: 0.91; 95% confidence interval: 0.71–1.16). However, patients with the Pro/Pro genotype exhibited a significantly younger age at breast cancer onset (55.2 ± 14.3 years) than Leu/Leu patients (60.6 ± 13.6 years; p = 0.04), which may reflect the ability of TGFβ to promote tumor progression. Mean TGFβ1 serum levels of Pro-allele carriers were 39.4 ± 7.4 ng/mL, whereas those of Leu/Leu subjects were 37.6 ± 6.0 ng/mL (p = 0.07). Thus, compared to a previous study of male subjects, we observed only a modest increase, if any, in TGFβ1 levels of female Pro-allele carriers. |
format | Online Article Text |
id | pubmed-3759865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-37598652013-09-03 The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer Taubenschuß, Eva Marton, Erika Mogg, Maurice Frech, Barbara Ehart, Lisa Muin, Dana Schreiber, Martin Int J Mol Sci Article The L10P single nucleotide polymorphism (SNP) is located in the signal sequence of the transforming growth factor β1 (TGFβ1) gene. The proline-encoding (Pro-) allele of this SNP has been associated with an increased breast cancer risk, which has been attributed to the elevated secretion of this TGFβ1 variant observed in vitro and in male subjects. Here we investigated the association of the L10P SNP with serum levels of TGFβ1 in female breast cancer patients and controls. We genotyped the L10P SNP in 276 breast cancer patients and 255 controls. Serum TGFβ1 concentrations were measured by enzyme-linked immunosorbent assay (ELISA) in a subset of the study population (n = 211). We found no evidence for an association of the L10P SNP with breast cancer risk (per-allele odds ratio: 0.91; 95% confidence interval: 0.71–1.16). However, patients with the Pro/Pro genotype exhibited a significantly younger age at breast cancer onset (55.2 ± 14.3 years) than Leu/Leu patients (60.6 ± 13.6 years; p = 0.04), which may reflect the ability of TGFβ to promote tumor progression. Mean TGFβ1 serum levels of Pro-allele carriers were 39.4 ± 7.4 ng/mL, whereas those of Leu/Leu subjects were 37.6 ± 6.0 ng/mL (p = 0.07). Thus, compared to a previous study of male subjects, we observed only a modest increase, if any, in TGFβ1 levels of female Pro-allele carriers. Molecular Diversity Preservation International (MDPI) 2013-07-24 /pmc/articles/PMC3759865/ /pubmed/23887657 http://dx.doi.org/10.3390/ijms140815376 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Taubenschuß, Eva Marton, Erika Mogg, Maurice Frech, Barbara Ehart, Lisa Muin, Dana Schreiber, Martin The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer |
title | The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer |
title_full | The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer |
title_fullStr | The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer |
title_full_unstemmed | The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer |
title_short | The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer |
title_sort | l10p polymorphism and serum levels of transforming growth factor β1 in human breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759865/ https://www.ncbi.nlm.nih.gov/pubmed/23887657 http://dx.doi.org/10.3390/ijms140815376 |
work_keys_str_mv | AT taubenschußeva thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT martonerika thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT moggmaurice thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT frechbarbara thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT ehartlisa thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT muindana thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT schreibermartin thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT taubenschußeva l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT martonerika l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT moggmaurice l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT frechbarbara l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT ehartlisa l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT muindana l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer AT schreibermartin l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer |